Zacks: Analysts Expect KemPharm (KMPH) Will Announce Earnings of -$0.70 Per Share

Analysts expect KemPharm (NASDAQ:KMPH) to post earnings of ($0.70) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for KemPharm’s earnings, with estimates ranging from ($0.72) to ($0.68). KemPharm posted earnings per share of ($0.84) during the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, May 9th.

According to Zacks, analysts expect that KemPharm will report full-year earnings of ($2.59) per share for the current fiscal year, with EPS estimates ranging from ($2.60) to ($2.57). For the next fiscal year, analysts forecast that the business will post earnings of ($2.48) per share, with EPS estimates ranging from ($3.09) to ($2.00). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that cover KemPharm.

How to Become a New Pot Stock Millionaire

KemPharm (NASDAQ:KMPH) last released its earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.04).



A number of equities analysts have weighed in on KMPH shares. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Thursday, April 5th. ValuEngine cut KemPharm from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Royal Bank of Canada set a $9.00 price target on KemPharm and gave the company a “buy” rating in a research note on Tuesday, January 16th. Roth Capital set a $10.00 price target on KemPharm and gave the company a “buy” rating in a research note on Monday, April 2nd. Finally, Oppenheimer set a $13.00 price target on KemPharm and gave the company a “buy” rating in a research note on Sunday, February 25th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $10.05.

NASDAQ KMPH traded down $0.03 during trading on Monday, reaching $6.50. 26,519 shares of the company’s stock were exchanged, compared to its average volume of 144,461. The company has a market cap of $98.56, a PE ratio of -2.20 and a beta of -0.34. The company has a quick ratio of 4.09, a current ratio of 4.09 and a debt-to-equity ratio of -1.56. KemPharm has a fifty-two week low of $2.45 and a fifty-two week high of $8.40.

A hedge fund recently raised its stake in KemPharm stock. Victory Capital Management Inc. lifted its stake in shares of KemPharm (NASDAQ:KMPH) by 26.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,077 shares of the specialty pharmaceutical company’s stock after purchasing an additional 34,114 shares during the quarter. Victory Capital Management Inc. owned about 1.11% of KemPharm worth $656,000 at the end of the most recent reporting period. 35.47% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect KemPharm (KMPH) Will Announce Earnings of -$0.70 Per Share” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/04/14/zacks-analysts-expect-kempharm-kmph-will-announce-earnings-of-0-70-per-share.html.

About KemPharm

KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply